https://www.selleckchem.com/products/enpp-1-in-1.html Biogas produced by anaerobic digestion is an important renewable energy carrier. Nevertheless, the high CO2 content in biogas limits its utilization to mainly heat and electricity generation. Upgrading biogas into biomethane broadens its potential as a vehicle fuel or substitute for natural gas. CO2-to-CH4 bioconversion represents one cutting-edge solution for biogas upgrading. In situ bioconversion can capture endogenous CO2 directly from the biogas reactor, is easy to operate, and provides an infrastructure for renewable electricity storage. Despite these advantages, several challenges need to be addressed to move in situ upgrading technologies closer to applications at scale. This opinion article reviews the state of the art of this technology and identifies some obstacles and opportunities of biological in-situ upgrading technologies for future development. Ibrutinib is a selective oral inhibitor of Bruton's tyrosine kinase. It is used in haematology to treat lymphoid B disorders. Haemorrhagic complications in dermatological surgery are occasionally associated with the use of anti-platelet and/or anticoagulant medication. Herein, we report a case of haemorrhage under ibrutinib following skin surgery. A 70-year-old male patient began treatment with ibrutinib for chronic lymphocytic leukaemia had 2 basal cell carcinomas of the face. The next day he had a persistent haemorrhage lasting more than 48h, with no effects on the final scarring result. Ibrutinib is a tyrosine kinase inhibitor whose mechanism of action plays a role in platelet adhesion. is known to cause haemorrhaging, either spontaneously or following invasive procedures, especially at the beginning of treatment. In the case of low-risk haemorrhagic procedures in which bleeding may be controlled by mechanical haemostasis, ibrutinib should be discontinued 3 days before and after surgery. In the event of recent initiation of ibrutinib and in the absence